Kuria Therapeutics to Participate in 45th Annual J.P. Morgan Healthcare Conference Week
SAN FRANCISCO, CA — Kuria Therapeutics, Inc., a biopharmaceutical company developing novel NRF2 activators for ophthalmic diseases, announced today that company leadership will attend the upcoming 45th Annual J.P. Morgan Healthcare Conference, taking place January 11–14, 2027, in San Francisco.
Chief Executive Officer Dr. Keith Ward will conduct one-on-one meetings with investors, prospective commercial partners, and industry leadership throughout the week. Discussions will center on updates from Kuria's lead program designed to offer the first non-surgical treatment option for Fuchs' dystrophy, progress in its IND-enabling toxicology program, and recent NIH grant funding.
Partnering & Meeting Requests
Kuria will participate in BIO Partnering @ JPM 2027 to meet with prospective collaborator and investor networks.
Registered BIO Partnering Attendees: Please submit meeting requests directly through the official BIO Partnering platform.
Direct Scheduling & General Inquiries: Parties outside the BIO network can coordinate meeting times by emailing KuriaJPM@kuriatx.com.
About Kuria Therapeutics, Inc.
Kuria Therapeutics is developing a new treatment paradigm for Fuchs’ dystrophy, a progressive corneal disease that currently requires late-stage patients to undergo invasive corneal transplant surgery. Kuria's lead program, a topically delivered NRF2 activator eye drop, targets the underlying oxidative stress and cellular degeneration of Fuchs' aiming to halt progression, restore visual acuity, and tap into a >$5 Billion market opportunity.
Beyond its targeted eye drop for Fuchs' dystrophy, Kuria’s pipeline leverages targeted NRF2 activation across additional high-impact indications, including glaucoma neuroprotection, cataract surgery recovery, and radiation dermatitis.
Contacts
Investor Relations and Media Kuria Therapeutics: Corporate Communication info@kuriatx.com